Search research articles
Contact Us
Filters
Showing results (561-570 of 731) with videos related to
Page
of 74
Sort By:
Plos One
|
August 20, 2015
The Number and Complexity of Pure and Recombinant HIV-1 Strains Observed within Incident Infections during the HIV and Malaria Cohort Study Conducted in Kericho, Kenya, from 2003 to 2006
Erik Billings, Eric Sanders-Buell, Meera Bose, et al.
Ebiomedicine
|
August 20, 2015
Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee
Nathan I Nicely, Kevin Wiehe, Thomas B Kepler, et al.
Plos One
|
April 28, 2018
Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations
Siriwat Akapirat, Chitraporn Karnasuta, Sandhya Vasan, et al.
Retrovirology
|
October 3, 2014
Aggregate complexes of HIV-1 induced by multimeric antibodies
Daniel J Stieh, Deborah F King, Katja Klein, et al.
Cardiovascular Drugs and Therapy
|
July 11, 2020
Ester Prodrugs of Malonate with Enhanced Intracellular Delivery Protect Against Cardiac Ischemia-Reperfusion Injury In Vivo
Hiran A Prag, Laura Pala, Duvaraka Kula-Alwar, et al.
AIDS Research and Human Retroviruses
|
December 24, 2016
Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens
Chitraporn Karnasuta, Siriwat Akapirat, Sirinan Madnote, et al.
Microorganisms
|
November 7, 2020
Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers
Frank Msafiri, Agricola Joachim, Kathrin Held, et al.
The Lancet. HIV
|
October 12, 2019
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
Giuseppe Pantaleo, Holly Janes, Shelly Karuna, et al.
The Journal of Infectious Diseases
|
November 19, 2014
HIV Type 1 Disease Progression to AIDS and Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable Subtype and T-Cell Immune Activation Levels
Michael A Eller, Marc S Opollo, Michelle Liu, et al.
Journal of Virology
|
June 23, 2021
Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth
Yifan Li, Hongjun Bai, Eric Sanders-Buell, et al.
Page
of 74
Search research articles
Search
Showing results (561-570 of 731) with videos related to
Sort By:
Page
of 74
Plos One
|
August 20, 2015
The Number and Complexity of Pure and Recombinant HIV-1 Strains Observed within Incident Infections during the HIV and Malaria Cohort Study Conducted in Kericho, Kenya, from 2003 to 2006
Erik Billings, Eric Sanders-Buell, Meera Bose, et al.
Ebiomedicine
|
August 20, 2015
Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee
Nathan I Nicely, Kevin Wiehe, Thomas B Kepler, et al.
Plos One
|
April 28, 2018
Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations
Siriwat Akapirat, Chitraporn Karnasuta, Sandhya Vasan, et al.
Retrovirology
|
October 3, 2014
Aggregate complexes of HIV-1 induced by multimeric antibodies
Daniel J Stieh, Deborah F King, Katja Klein, et al.
Cardiovascular Drugs and Therapy
|
July 11, 2020
Ester Prodrugs of Malonate with Enhanced Intracellular Delivery Protect Against Cardiac Ischemia-Reperfusion Injury In Vivo
Hiran A Prag, Laura Pala, Duvaraka Kula-Alwar, et al.
AIDS Research and Human Retroviruses
|
December 24, 2016
Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens
Chitraporn Karnasuta, Siriwat Akapirat, Sirinan Madnote, et al.
Microorganisms
|
November 7, 2020
Frequent Anti-V1V2 Responses Induced by HIV-DNA Followed by HIV-MVA with or without CN54rgp140/GLA-AF in Healthy African Volunteers
Frank Msafiri, Agricola Joachim, Kathrin Held, et al.
The Lancet. HIV
|
October 12, 2019
Safety and immunogenicity of a multivalent HIV vaccine comprising envelope protein with either DNA or NYVAC vectors (HVTN 096): a phase 1b, double-blind, placebo-controlled trial
Giuseppe Pantaleo, Holly Janes, Shelly Karuna, et al.
The Journal of Infectious Diseases
|
November 19, 2014
HIV Type 1 Disease Progression to AIDS and Death in a Rural Ugandan Cohort Is Primarily Dependent on Viral Load Despite Variable Subtype and T-Cell Immune Activation Levels
Michael A Eller, Marc S Opollo, Michelle Liu, et al.
Journal of Virology
|
June 23, 2021
Limited Evidence for a Relationship between HIV-1 Glycan Shield Features in Early Infection and the Development of Neutralization Breadth
Yifan Li, Hongjun Bai, Eric Sanders-Buell, et al.
Page
of 74